TNFRSF17 and Miyoshi myopathy: Taken together, among heavily previously treated patients, the majority with MM refractory to ADC (versus CAR‐T) anti‐BCMA therapy, X‐containing regimens had impressive potency with durable responses and ≥6 month tolerability.